Parameter
| Biomarker | TMAO | Full name | Trimethylamine N-oxide | Molecular Type | metabolites |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | 75.11 Da | Core Functional Dimensions | Susceptibility, prognosis |
| Disease | Coronary heart disease (CHD) | Disease Subtypes | / | ||
| Organ | Liver (metabolism of gut microbiota-derived TMA) | Test Sample / Technology Platform | Serum/plasma (LC-MS and GC-MS) | ||
| Pathobiological Mechanisms | Metabolites of gut microbiota (derived from choline and L-carnitine); Promote macrophage foaming, inhibit endothelial function, and accelerate atherosclerosis | ||||
| Clinical Availability Status | Research validation (risk) : large-scale cohort (n = 1273) confirmed that TMAO > 5 μmol/L 62% increased risk of coronary heart disease, in patients with AMI were significantly higher than stable coronary heart disease (p < 0.01); It is not included in clinical guidelines, but only used as an indicator for scientific research and screening of high-risk populations | ||||
| Notes and Dynamics | It is greatly affected by diet (the intake of red meat and egg yolk can increase), so standardized diet is needed before testing; It is related to the composition of intestinal flora, which can guide the "diet-microbiota" intervention treatment | ||||